Assignee
SERMONIX PHARMACEUTICALS INC
US·2 granted patents·4 pending applications·2 citations·filing 2021–2024
Top patents by PatentIndex Score
6 records- 0190US12023321B2Lasofoxifene treatment of aromatase-resistant ER+cancerSERMONIX PHARMACEUTICALS INC·Filed 2023·Granted Jul 2, 2024·2 cites·30 claims
- 0282US12433866B2Lasofoxifene treatment of aromatase-resistant ER+ cancerSERMONIX PHARMACEUTICALS INC·Filed 2024·Granted Oct 7, 2025·0 cites·30 claims
- 0370US2023149350A1Lasofoxifene treatment of aromatase-resistant er+ cancerSERMONIX PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 0466US2024122896A1Lasofoxifene combination treatment of er+ breast cancer that has progressed on a cdk4/6 inhibitorSERMONIX PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 0564US2023381138A1Lasofoxifene combination treatment of er+ breast cancer that has progressed on a cdk4/6 inhibitorSERMONIX PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 0653US2022133691A1Lasofoxifene treatment of vva and osteoporosis in survivors of breast cancer and other malignanciesSERMONIX PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →